Cerliponase alfa - Biologic Drug Details

Summary for cerliponase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for cerliponase alfa

Recent Clinical Trials for cerliponase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
David L Rogers, MD	Phase 1/Phase 2

See all cerliponase alfa clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for cerliponase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for cerliponase alfa Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for cerliponase alfa Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Cerliponase Alfa

Introduction

Cerliponase alfa, marketed as Brineura, is a biologic drug approved for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare and devastating neurodegenerative disorder. Here, we delve into the market dynamics and financial trajectory of this critical therapeutic agent.

Market Size and Growth

The global Batten disease treatment market, which includes cerliponase alfa, is projected to grow significantly. As of 2022, the market size was USD 41.39 million, and it is expected to reach USD 57.89 million by 2030, with a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period of 2023 to 2030[1].

Segmentation and Key Markets

The market for cerliponase alfa is segmented based on several factors, including types of Batten disease (Congenital NCL, Infantile NCL, Late Infantile NCL, and Adult NCL), drugs (cerliponase alfa, valproic acid, and levetiracetam), therapy types (occupational therapy and physical therapy), treatment methods (medication and supportive care), routes of administration (oral and parenteral), distribution channels (hospital pharmacy, retail pharmacy, and online pharmacy), and end users (hospitals, homecare, specialty clinics, and others)[1].

Clinical Effectiveness and Safety

Cerliponase alfa has demonstrated significant clinical effectiveness in slowing the loss of ambulation in pediatric patients with CLN2 disease. It is an enzyme replacement therapy that restores the levels of tripeptidyl peptidase-1 (TPP1) in patients. Studies have shown that patients treated with cerliponase alfa experience a significantly longer time to decline in motor and language scores compared to those receiving symptomatic therapy[3][4][5].

Expanded Indications

Recently, the FDA approved an expanded indication for cerliponase alfa to include children of all ages with CLN2 disease, whether symptomatic or asymptomatic. This expansion was supported by a phase 2 open-label trial that showed reduced decline in motor function and delayed disease onset, even in children under 3 years old[4].

Cost-Effectiveness Analysis

Despite its clinical effectiveness, cerliponase alfa faces challenges in terms of cost-effectiveness. A study conducted in the Republic of Serbia found that cerliponase alfa was not more economical than symptomatic therapy when using typical pharmacoeconomic analysis. The treatment is associated with high direct costs, which can be a barrier to accessibility for many patients[2].

Financial Impact and Funding

The financial impact of cerliponase alfa is significant due to its high cost. However, reviews have shown that the total costs were lower than anticipated in some regions. For instance, in Australia, the total recorded costs were lower than expected due to lower than expected uptake of treatment and less than full dosing for some patients. The review also suggested that patients accessing the treatment may have performed better than expected, potentially reducing the incremental cost-effectiveness ratio (ICER)[5].

Pricing and Value for Money

The pricing of cerliponase alfa is a critical factor in its financial trajectory. The drug is close to the average price of other drugs listed on the Life Saving Drugs Program (LSDP) in Australia. However, there is a recommendation for reassessing the pricing to improve value for money when the current agreement with the sponsor expires[5].

Adverse Effects and Safety Profile

Cerliponase alfa has a safety profile that includes common adverse events such as fever, vomiting, seizures, and device-related complications. Hypersensitivity reactions, particularly in children under 3 years old, are also noted. Despite these adverse effects, the overall safety profile is similar to that observed in prior studies[4].

Patient and Caregiver Impact

The treatment has been described by families as "life-saving," significantly improving the quality of life for patients. It helps in retaining mobility, forms of communication, independence, and socialization, which are crucial for the well-being of patients and their caregivers[5].

Future Outlook

The future outlook for cerliponase alfa is promising, given its expanded indications and demonstrated clinical effectiveness. However, addressing the cost-effectiveness and accessibility issues will be crucial for making this treatment available to all patients with CLN2 disease.

Key Takeaways

• Market Growth: The global Batten disease treatment market, including cerliponase alfa, is expected to grow with a CAGR of 5.4% from 2023 to 2030.
• Clinical Effectiveness: Cerliponase alfa significantly slows the loss of ambulation and delays disease onset in CLN2 patients.
• Cost-Effectiveness: Despite clinical benefits, cerliponase alfa faces challenges in cost-effectiveness compared to symptomatic therapy.
• Financial Impact: Total costs have been lower than expected in some regions due to lower uptake and dosing.
• Pricing and Value: There is a need to reassess pricing to improve value for money.
• Safety Profile: The drug has a manageable safety profile with common adverse events and hypersensitivity reactions in younger patients.

FAQs

Q: What is cerliponase alfa used for? A: Cerliponase alfa is used to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency[3].

Q: How is cerliponase alfa administered? A: Cerliponase alfa is administered via intraventricular infusion into the brain using sterile technique to reduce the risk of infection[4].

Q: What are the common adverse effects of cerliponase alfa? A: Common adverse effects include fever, vomiting, seizures, device-related complications, and hypersensitivity reactions, particularly in children under 3 years old[4].

Q: Is cerliponase alfa cost-effective? A: Cerliponase alfa is not more economical than symptomatic therapy based on typical pharmacoeconomic analysis, despite its clinical benefits[2].

Q: What is the current market size and growth projection for the Batten disease treatment market? A: The global Batten disease treatment market was USD 41.39 million in 2022 and is expected to reach USD 57.89 million by 2030, with a CAGR of 5.4% from 2023 to 2030[1].

Sources

1. Databridge Market Research: Global Batten Disease Treatment Market Size, Demand & Industry Analysis.
2. PubMed: Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2.
3. DrugBank: Cerliponase alfa: Uses, Interactions, Mechanism of Action.
4. Neurology Live: FDA Approves Expanded Indication for Cerliponase Alfa to Treat CLN2 Disease in Children Under 3 Years.
5. Australian Government Department of Health: Cerliponase alfa (Brineura®) 24-month Review.

Last updated: 2024-12-18